Oncolytics Biotech Inc. (ONCY) |
1.27 0.03 (2.42%) 10-10 10:07 |
Open: | 1.27 |
High: | 1.3 |
Low: | 1.26 |
Volume: | 117,221 |
Market Cap: | 127(M) |
PE Ratio: | -4.88 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 1.51 |
Resistance 1: | 1.37 |
Pivot price: | 1.33 |
Support 1: | 1.14 |
Support 2: | 0.95 |
52w High: | 1.51 |
52w Low: | 0.33 |
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
EPS | -0.270 |
Book Value | 0.060 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -74.6 |
Return on Equity (ttm) | -249.3 |
Fri, 10 Oct 2025
Oncolytics Biotech's (ONCY) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Fri, 10 Oct 2025
Oncolytics Biotech (NASDAQ:ONCY) Trading Down 3.1% - Should You Sell? - MarketBeat
Mon, 29 Sep 2025
Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study - PR Newswire
Tue, 16 Sep 2025
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion - PR Newswire
Mon, 08 Sep 2025
Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions - PR Newswire
Tue, 02 Sep 2025
Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors - PR Newswire
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |